The Impact of Common Neuropsychiatric Conditions on Cognitive Function

Elena Beyzarov, PharmD
Published Online: Thursday, April 5, 2012
Follow Pharmacy_Times:

Pharmacy Times Office of Continuing Professional Education


The Impact of Common Neuropsychiatric Conditions on Cognitive Function

Elena Beyzarov, PharmD

Scientific Director

Pharmacy Times Office of Continuing Professional Education


Elena Beyzarov, PharmD, has no relevant affiliations or financial relationships to disclose related to this activity.

Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Donna Fausak of the Pharmacy Times Office of Continuing Professional Education have no relevant affiliations or financial relationships to disclose related to this activity.

Bea Riemschneider, Jennifer Barrio, and David Allikas of Pharmacy Times Editorial have no relevant affiliations or financial relationships to disclose related to this activity.


Educational Objectives

Upon completion of this educational activity, participants should be able to:

  1. Examine the impact of schizophrenia, multiple sclerosis (MS), and Parkinson's disease (PD) on cognitive function.
  2. Understand the prevalence and pathophysiology of cognitive impairment in schizophrenia, MS, and PD.
  3. Evaluate evolving strategies aimed at minimizing neurodegeneration in schizophrenia, MS, and PD.
  4. Discuss the implications for the pharmacist in regard to identifying and counseling patients with cognitive impairment.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: March 15, 2012

Expiration date: March 15, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online

Click here to view this activity.



Related Articles
The FDA is permitting marketing of a replaceable urinary prosthesis for female adults with impaired detrusor contractility.
Neuroprotective nutrients appear to enhance cognition, memory, and other impaired functions seen in patients with Alzheimer's disease.
In response to the recent article by Gary M. Franklin, MD, MPH, titled “Opioids for chronic non-cancer pain: A position paper of the American Academy of Neurology,” we wish to address a number of issues.
The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.
Latest Issues
$auto_registration$